Photo of Grover C. Bagby, M.D.

Grover C. Bagby M.D.

Dr. Bagby is retired from his OHSU practice and from his role as founding director of the OHSU Knight Cancer Institute, but remains an active member of the hematology/oncology section at the Portland VA Medical Center. He is experienced in the clinical management of acute leukemia, myelodysplasia and bone marrow failure syndromes and has ongoing funded active research projects in each one of these areas. His specialized research focuses on defining the molecular genetic determinants of leukemogenesis. His long-term goal is to develop pharmaceutical agents that can prevent the development of leukemia in patients at high risk.

Education

  • M.D., Baylor College of Medicine, 0 0 1968
  • Residency:

    • Ben Taub General Hospital, Houston; Baylor Affiliated Medical Residency, Houston; Oregon Health & Science University, Portland
  • Fellowship:

    • Hematology, Oregon Health & Science University, 1972 hematology, Oregon Health & Science University, 1976
  • Certifications:

    • American Board of Internal Medicine (internal medicine), 1974 American Board of Internal Medicine (Hematology), 1976

Memberships and associations

  • Master, American College of Physicians Association of American Physicians American Society for Clinical Investigation American Society of Hematology International Society for Experimental Hematology American Association for Cancer Research

Publications

  • "P38 mitogen-activated protein kinase inhibition enhances invitro erythropoiesis of Fanconi anemia, complementation group A-deficient bonemarrow cells." Experimental Hematology  In: , Vol. 43, No. 4, 01.04.2015, p. 295-299.
  • "Oxymetholone therapy of fanconi anemia suppresses osteopontin transcription and induces hematopoietic stem cell cycling." Stem Cell Reports  In: , Vol. 4, No. 1, 13.01.2015, p. 90-102.
  • "FANCA and FANCC modulate TLR and p38 MAPK-dependent expression of IL-1β in macrophages." Blood In: , Vol. 122, No. 18, 31.10.2013, p. 3197-3205.
  • "The PI3K/Akt1 pathway enhances steady-state levels of FANCL." Molecular Biology of the Cell In: , Vol. 24, No. 16, 15.08.2013, p. 2582-2592.
  • "Immune response gene profiles in the term placenta depend upon maternal muscle mass." Reproductive Sciences In: , Vol. 19, No. 10, 10.2012, p. 1041-1056.
  • "FANCL ubiquitinates β-catenin and enhances its nuclear function." Blood In: , Vol. 120, No. 2, 12.07.2012, p. 323-334.
  • "p38 MAPK inhibition suppresses the TLR-hypersensitive phenotype in FANCC and FANCA-deficient mononuclear phagocytes." Blood In: , Vol. 119, No. 9, 01.03.2012, p. 1992-2002.
  • "The fate of granulosa cells following premature oocyte loss and the development of ovarian cancers." International Journal of Developmental Biology In: , Vol. 56, No. 10-12, 2012, p. 949-958.
  • "TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms." Blood In: , Vol. 118, No. 24, 08.12.2011, p. 6392-6398.
  • "Aplastic Anemia and Related Bone Marrow Failure States."  Goldman's Cecil Medicine: Twenty Fourth Edition. Vol. 1 Elsevier Inc., 2011. p. 1083-1090.
  • "The stem cell fitness landscape and pathways of molecular leukemogenesis." Frontiers in Bioscience - Scholar In: , Vol. 3 S, No. 2, 01.01.2011, p. 487-500.
  • "Fancd2-/- mice have hematopoietic defects that can be partially corrected by resveratrol." Blood  In: , Vol. 116, No. 24, 09.12.2010, p. 5140-5148.
  • "Genetic disruption of both Fancc and Fancg in mice recapitulates the hematopoietic manifestations of Fanconi anemia." Blood  In: , Vol. 116, No. 16, 21.10.2010, p. 2915-2920.
  • "Human FANCC is hypomorphic in murine Fancc-deficient cells." Blood In: , Vol. 116, No. 12, 23.09.2010, p. 2057-2060.
  • "TLR8-dependent TNF-α overexpression in Fanconi anemia group C cells." Blood In: , Vol. 114, No. 26, 17.12.2009, p. 5290-5298.
  • "Preface." Hematology/Oncology Clinics of North America  In: , Vol. 23, No. 2, 04.2009.
  • "Myelodysplasia and Acute Leukemia as Late Complications of Marrow Failure : Future Prospects for Leukemia Prevention." Hematology/Oncology Clinics of North America  In: , Vol. 23, No. 2, 04.2009, p. 361-376.
  • "Introducing "e-Blood"." Blood In: , Vol. 113, No. 19, 2009, p. 4488.
  • "Expression profiling of the ovarian surface kinome reveals candidate genes for early neoplastic changes." Translational Oncology In: , Vol. 2, No. 4, 2009, p. 341-349.
  • "Global rank-invariant set normalization (GRSN) to reduce systematic distortions in microarray data." BMC Bioinformatics In: , Vol. 9, 520, 04.12.2008.
  • "TAT-mediated intracellular delivery of NPM-derived peptide induces apoptosis in leukemic cells and suppresses leukemogenesis in mice." Blood  In: , Vol. 112, No. 6, 15.09.2008, p. 2474-2483.
  • "Cigarette smoke induces genetic instability in airway epithelial cells by suppressing FANCD2 expression." British Journal of Cancer In: , Vol. 98, No. 10, 20.05.2008, p. 1653-1661.
  • "Discovering early molecular determinants of leukemogenesis." Journal of Clinical Investigation In: , Vol. 118, No. 3, 03.2008, p. 847-850.
  • "TNF-α induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells." Journal of Clinical Investigation  In: , Vol. 117, No. 11, 01.11.2007, p. 3283-3295.
  • "In response [6]." Cancer Research  In: , Vol. 67, No. 6, 15.03.2007, p. 2902-2903.
  • "Bone marrow failure as a risk factor for clonal evolution : prospects for leukemia prevention." Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program  In: , 2007, p. 40-46.
  • "Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer." Cancer Research In: , Vol. 66, No. 18, 15.09.2006, p. 9017-9025.
  • "Evaluation and lead optimization of anti-malarial acridones." Experimental Parasitology In: , Vol. 114, No. 1, 09.2006, p. 47-56.
  • "Constitutional Marrow Failure : Introduction." Seminars in Hematology In: , Vol. 43, No. 3, 07.2006, p. 145-146.
  • "Fanconi Anemia." Seminars in Hematology In: , Vol. 43, No. 3, 07.2006, p. 147-156.

Additional information

Edit profile